

PCR (ef1a) (Lafont et al. 2021). I (arf1), (gaph) (Hafner et al. 2016). T. ANOVA (P < 0.05).

Identifying and Cloning the Coding Sequence of *CgHPX2*

T. *CgHPX2* (NCBI, LOC105324712). T. S2. T. PCR (V, C). 1.5%.

Bioinformatics Analysis of *CgHPX2*

T. (I) (M) C I/M T E PA (//). T. CD-5 (NCBI //). T. (Ly) B L CA (ESP 23.0 (P 2014)). T. MEGA 7.0 (K) (ML) 1000.

RNA Location Pattern Analysis of *CgHPX2* by in Situ Hybridization

T. (TISH) (ISH) RNA DNA T S2 T7 (GAT CACTAATACGACTCACTATAGGG). T. PCR DNA (T, USA).

T. PCR DIG-RNA (R, S). T. TISH (A) (Y) (2% NBT/BCIP (R, S) 1. 2. 0.5% (S) (H. 2015). T. (L 2021; 2021). A TISH (S) (O) (J).


Luciferase Vector Construction and Site-Directed Mutagenesis

T. *CgHPX2* GL3-B (P, USA) C E II O S C K (V, C). S 5 (P1: 2011 +216, P2: 1726 +216, P3: 1519 +216, P4: 1221 +216, P5: 453 +216, P6: 351 +216) *CgHPX2* DNA I. DNA3.1 (P, USA) CDS *CgPOU2F1* *CgSOX5* DNA3.1. T. M 2E 2SF 2M 2V2 (V, C). A. T. S2.

Cell Culture, Transient Transfections, and Dual-Luciferase Reporter Assays

HEK-293T DMEM (S, C) 10% (Hy, USA) 1% 1 (Hy, USA) 237 C 5% CO₂. T. 24- (CORNING, USA) 70–90% (I, CA, USA) T. RL-TK (P, USA) -2 (F) 500 10 RL-TK 24- (F) -2.

Fig. 1 T9 0 2 0 29
 CgHPX2 y% 9 9 2
 05 29 CgHPX2. A T9
 9 0 0 y% 29
 29 CgHPX2 0 . T9
 . 2 2 9 0 y% 29
 C HP 2 2 9 44%
 . 9 9 0 3% 9 2
 0 0 2 9 0 B 2 9 9 -
 0 0 2 y% 29 29
 CgHPX2 0 ; C 9
 . y% 9 9 2 05 CgHPX2
 0 0 y% 29
 9 (ML) 9 2 . T9
 9 0 2 2 9 9 0 0
 2 9 0 2 0 0 0
 1000 9 0 0



H 9 9 9 0 0 9 9 2 9 9 9 29 9 9 29
 9 2 29 9 9 RNA 9 9 0 9 9 CgHPX2 29 9 9 29 0 9 0 0 0 0
 (P < 0.05) (F . 2A). T 9 9 9 0 0




Fig. 2 T9 RNA 9 9 0 9 0 CgHPX2. A




Fig. 4 *CgHPX2* RNAi larvae. **I** Control larvae showing normal development. **II** Larvae treated with *CgHPX2* RNAi showing developmental delays and abnormalities. Stages are labeled: Fertilized egg, Multicellular stage, Blastula stage, Gastrula stage, Trochophore stage, Early D-shaped larvae, Late D-shaped larvae, Umbo larvae, and Eyed larvae.

| Gene | Stage | Survival (%) | Abnormalities (%) |
|-----------------|-----------------------|--------------|-------------------|
| <i>CgHPX2</i> | Fertilized egg | 100 | 0 |
| | Multicellular stage | 100 | 0 |
| | Blastula stage | 100 | 0 |
| | Gastrula stage | 100 | 0 |
| <i>CgPOU2F1</i> | Trochophore stage | 100 | 0 |
| | Early D-shaped larvae | 100 | 0 |
| | Late D-shaped larvae | 100 | 0 |
| | Eyed larvae | 100 | 0 |
| <i>CgSOX5</i> | Fertilized egg | 100 | 0 |
| | Multicellular stage | 100 | 0 |
| | Blastula stage | 100 | 0 |
| | Gastrula stage | 100 | 0 |
| <i>HPX2</i> | Trochophore stage | 100 | 0 |
| | Early D-shaped larvae | 100 | 0 |
| | Late D-shaped larvae | 100 | 0 |
| | Eyed larvae | 100 | 0 |





Fig. 5 Schematic of the CgHPX2 promoter region and luciferase reporter assays. **A** Genomic context of the CgHPX2 promoter region showing various transcription factor binding sites (GATA-1, UREB, POU2F1, SOX5, etc.) and their positions relative to the TATA box. **B** Schematic of five luciferase reporter constructs (Luc) with different promoter lengths: -2011/+216 (b), -1726/+216 (a), -1519/+216 (c), -1221/+216 (d), and -351/+216 (e). **C** Schematic of wild-type and mutated POU2F1 binding sites (TTTGTATGAAAAATAA vs TTTGTCGCTCGGGCAAA) and a corresponding bar graph of relative luciferase activity. **D** Schematic of wild-type and mutated SOX5 binding sites (CGTTGCACATCTTGAAGTT vs CGTTCACCCACCGACATT) and a corresponding bar graph. Both bar graphs show activity under various conditions of pGL3-Basic, pRL-TK, P4, and pcDNA3.1-POU2F1 or pcDNA3.1-SOX5.

CgPOU2F1 and CgSOX5 are Located in the Nucleus in HEK-293 T Cells

HEK-293 T cells were transfected with CgPOU2F1-EGFP, CgSOX5-EGFP, or EGFP-EGFP. Cells were stained with DAPI (blue) to visualize the nucleus. The localization of CgPOU2F1 and CgSOX5 in the nucleus was confirmed by immunofluorescence microscopy.

HEK-293 T cells were transfected with CgPOU2F1-EGFP, CgSOX5-EGFP, or EGFP-EGFP. Cells were stained with DAPI (blue) to visualize the nucleus. The localization of CgPOU2F1 and CgSOX5 in the nucleus was confirmed by immunofluorescence microscopy.

Fig. 6 Schematic of the CgPOU2F1 and CgSOX5 promoter regions and their localization in HEK-293 T cells. **A** Schematic of the CgPOU2F1 promoter region. **B** Schematic of the CgSOX5 promoter region. **C** Immunofluorescence microscopy images of HEK-293 T cells transfected with CgPOU2F1-EGFP, CgSOX5-EGFP, or EGFP-EGFP. Cells were stained with DAPI (blue) to visualize the nucleus. The localization of CgPOU2F1 and CgSOX5 in the nucleus was confirmed by immunofluorescence microscopy.



CgPOU2F1 and CgSOX5 Knockdown Led to a Decrease in CgHPX2 Expression

T. 29 y% 29 2 CgPOU2F1
 CgSOX5 29 9 2 CgHPX2, CgPOU2F1
 CgSOX5 RNA 29 9 .
 T. 99 900 RNA 2 9 E. coli 2 2
 99 9 2 0.4 MIPTG 237 7C 4 .
 B RNA 9 2 POU2F1 SOX5
 99 29 9 9 2 T7 2 99 9 9
 29 IPTG- 9 E. coli (F . S6), 2 29 -
 9 9 9 RNA E. coli.
 T 9 2 2 9 2 9 9 9 99 9 9 , PCR 9 2 2
 2 9 2 2 2 9 9 9 9 2 9 99
 CgPOU2F1 CgSOX5 RNA 2 2y% 9
 2 9 2 29 2 y7 y14,
 9 2 9 y(F . S7).
 C 9 2 29 9 2 EGFP RNA-
 9 99 2 , 29 9 99 9 9 29 9 9
 CgHPX2 2 2y% 9 9 RNA -29 2
 (F . 7). I POU2F1 RNA 9 99 2 -29 2
 , 29 9 9 9 CgHPX2 2 2y%
 9 9 2 y69% 88% 9 2 29 9 29
 2 y7 y14, 9 2 9 y I SOX5
 RNA 9 99 2 -29 2 , CgHPX2 RNA
 9 99 9 9 2 57% y14.

Discussion

H 9-9 2 2 9 9 29 9 2 9 9 -
 y% 99 9 9 9 9 9
 T 9 29 2 9 9 2 9 29 2 y%
 I 9 99 2 9 2 29 2 y 2 9 9
 9 9 9 2 2 (S 9 2 . 2017). H 9 9 2 2

9 9 y% 29 y% 9 2 2 9 2 9 2 2
 (L 9 2 . 2008). CgHPX2 9 2 2 29 2 y%
 9 2 2 2 2 9 2 y% -
 9 2 (MPO), 29 2 (LPO), 9 2 9 -
 2 (EPO), 2y% 9 2 (TPO) (L .
 9 2 . 2008). P. y% 9 9 2 y% CgHPX2 2 2
 9 2 2 29 29 9 2 9 9 2 2 CgHPX2 2
 2 9 2 9 9 9 9 9 2 (99%
 2 y%), 2 2 2 2 2 9 2 2 2
 2 y% 9 2 2 . I *Sepia officinalis*, 9 -
 9 9 2 2 29 29 y% 9 9 9 -
 y% 29 2 2 (C. 9 2014). T 2 9 2 2
 CgHPX2 2 y% 2 2 29 2 y% 9 9 y% -
 29 2 2 2 2 2 29 9 RNA 9 9 -
 9 2 (F 9 2 . 2019).
 2 9 9 9 y% 2 9 2 y% -
 9 99 2 9 y% 29 2 29
 2 , 2 2 (C. 9 2014; D
 9 2 . 2017; T 9 2 1968). I 2 2 y% 2 -
 9 99 y% 29 9 9 2 2 CgHPX2 2 9
 y% 9 99 29 2 9 2 9 9 2 2
 29 2 2 2 2 29 2 2 2 2
 2 2 2 CgHPX2 y% 9 9 2 9 2 2
 29 9 9 , 29 2 9 9 2
 9 2 2 . F 2 y% 29 2 2 2 2
 9 y% 9 , 2 9 9 2 2 -
 2 9 9 2 y% 9 9 99 29 9 9 -
 2 2 2 2 2 9 29 9 9 2 9 -
 9 2 , 9 2 y% 2 2 2 2 2 29
 29 2 2 9 2 2 2 2 9 9 2 2 . S y%
 29 2 9 2 9 2 2 2 2 29 29
 2 . T. 9 9 99 CgHPX2 9 9 29 9

Fig. 7 RNA
 29 CgPOU2F1 CgSOX5
 9 9 . A T 9 9 2 9 9 9 99
 9 9 2 CgHPX2 29 U
 9 2 9 2 9 99
 2 POU2F1 EGFP.
 B T 9 9 2 9 9 9 99
 9 9 2 CgHPX2 29 U
 9 2 9 2 9 99 2
 EGFP SOX5. T. 9 2
 9 9 99 2 9 SD
 (n=3). D 9 9 29 2 2 -
 2 2 2 9 9 9 2
 P<0.05

